Gyu Yeol Kim

Ulsan University Hospital, Urusan, Ulsan, South Korea

Are you Gyu Yeol Kim?

Claim your profile

Publications (10)17.7 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the effectiveness of endoscopic submucosal resection with a ligation device (ESMR-L) on histologic complete resection for the treatment of small rectal carcinoid tumors in comparison with the treatment with endoscopic mucosal resection (EMR) alone. Thirty-five patients with small rectal carcinoid tumors were enrolled prospectively for ESMR-L, and we retrospectively reviewed 74 carcinoid tumor patients who underwent EMR. The comparison between ESMR-L and EMR groups was analyzed including endoscopic and histologic complete resection and complications after resection. We also evaluated the associations of histologic complete resection with clinical and procedure-related factors. The histologic complete resection rate was significantly higher in ESMR-L than in EMR (94.3% vs. 75.7%, P=0.019). In addition, the resection time was significantly shorter in ESMR-L than in EMR (4.16±1.48 min vs. 5.11±2.47 min, respectively, P=0.014). Moreover, previously biopsied rectal carcinoid tumors were significantly associated with histologic incomplete resection, especially in patients who underwent EMR (odds ratio, 6.28; 95% confidence interval, 1.92-20.58; P=0.002). Compared with EMR, ESMR-L is a safe and effective method for histologic complete resection of small rectal carcinoid tumors, especially in patients with previously biopsied carcinoid tumors.
    Surgical laparoscopy, endoscopy & percutaneous techniques 04/2014; · 0.88 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Severe sepsis and septic shock caused mainly by bacterial infections are life-threatening conditions that urge the development of novel therapies. However, host responses to and pathophysiology of sepsis have not been clearly understood, which remains a major obstacle for the development of effective therapeutics. Recently, we have shown that stimulation of costimulatory molecule, CD137, enhanced survival of mice infected with the Gram-positive (G+) intracellular bacteria Listeria monocytogenes, but decreased survival in a polymicrobial sepsis model. Herein, we report that CD137 deficiency or blocking of CD137 signaling decreased anti-bacterial responses of mice infected with G+ bacteria (Staphylococcus aureus, Streptococcus pneumonia, Enterococcus faecalis), but increased these responses in mice infected with Gram-negative (G-) bacteria (Escherichia coli, Pseudomonas aeruginosa, Salmonella typhimurium). Consistent with these findings, stimulation of CD137 by administration of agonistic antibody enhanced anti-bacterial responses against G+, whereas, it decreased these responses against G- bacteria. Neutrophils were responsible for CD137-mediated opposite roles in control of G+ and G- bacterial infection. Stimulation of CD137 enhanced anti-bacterial activities of neutrophils against S. aureus but decreased these activities against E. coli, while CD137 blocking decreased neutrophil anti-bacterial responses in vivo and in vitro. Furthermore, we found combined signaling of CD137 and TLR2 induced synergistic production of TNF-α and IL-6 by neutrophils, but combined signaling of CD137 and TLR4 did not. Our data strongly suggest that CD137 may play a dual role in sepsis in association with TLRs.
    Infection and immunity 04/2013; · 4.21 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The development of gastric cancer (GC) is closely related to chronic inflammation caused by Helicobacter pylori infection, and herpes virus entry mediator (HVEM) is a receptor expressed on the surface of leukocytes that mediates potent inflammatory responses in animal models. However, the role of HVEM in human GC has not been studied. Previously, we showed that the interaction of HVEM on human leukocytes with its ligand LIGHT induces intracellular calcium mobilization, which results in inflammatory responses including induction of proinflammatory cytokine production and anti-bacterial activities. In this study, we report that leukocytes from GC patients express lower levels of membrane HVEM (mHVEM) and have lower LIGHT-induced bactericidal activities than those from healthy controls (HC). In contrast, levels of soluble HVEM (sHVEM) in the sera of GC patients were significantly higher than in those of HC. We found that monocyte membrane-bound HVEM is released into the medium when cells are activated by proinflammatory cytokines such as TNF-α and IL-8, which are elevated in the sera of GC patients. mHVEM level dropped in parallel with the release of sHVEM, and release was completely blocked by the metalloprotease inhibitor, GM6001. We also found that the low level of mHVEM on GC patient leukocytes was correlated with low LIGHT-induced bactericidal activities against H. pylori and S. aureus and production of reactive oxygen species. Our results indicate that mHVEM on leukocytes and sHVEM in sera may contribute to the development and/or progression of GC.
    Experimental and Molecular Medicine 11/2011; 44(2):149-58. · 2.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Heat shock protein (Hsp) in tumor cells has been proposed to enhance their resistance to chemotherapeutic agents. In the present study, we investigated the influence of Hsp expression on the irinotecan resistance of human colorectal cancer cells. Among eight Hsp genes tested in this study, we confirmed that the expression of Hsp27 correlated with irinotecan resistance in colorectal cancer cells. Specific inhibition of Hsp27 expression using an antisense oliogodeoxynucleotide increased the irinotecan sensitivity. On the contrary, an overexpression of Hsp27 decreased the irinotecan sensitivity in colorectal cancer cells. Elevated expression of Hsp27 decreased caspase-3 activity in colorectal cancer cells. The expression level of Hsp27 determined by immunohistochemical analysis correlated with the clinical response to irinotecan in colorectal cancer patients. Hsp27 expression levels of irinotecan-non-responder (mean staining score, 6.28; proportion of high staining score, 64.2%) were significantly higher compared to those of irinotecan-responder (mean staining score, 3.16; proportion of high staining score, 33.3%) (P for t-test=0.045). These findings suggest that Hsp27 is involved in the irinotecan resistance of colorectal cancer cells possibly by reducing caspase-3 activity.
    FEBS Letters 04/2007; 581(8):1649-56. · 3.58 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatocellular carcinoma (HCC) is a highly invasive tumor that metastasizes hematogenously and lymphogenously to distant site. Frequent sites are lung, regional lymph node, bone, and adrenal gland. But metastasis to the gastrointestinal (GI) tract is rare, and most common site is stomach. Metastasis to the small intestine is extremely rare. Moreover, metastatic HCC of the small bowel causing intussusception has not been reported until now. Here, we report a case of metastasis of HCC to the small bowel manifested by intussusception.
    World Journal of Gastroenterology 04/2006; 12(12):1969-71. · 2.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Docetaxel plus cisplatin (DP) is a combination chemotherapy regimen that is active against untreated advanced gastric cancer. We evaluated the feasibility of DP treatment in patients with recurring or metastatic gastric cancer who had been previously treated with other chemotherapy regimens. The DP regimen consisted of docetaxel (75 mg/m(2) i.v.) and cisplatin (60 mg/m(2) i.v.) over 1 h on Day 1 every 4 weeks for a maximum of nine cycles. Thirty-seven patients (28 men, 9 women; median age, 53 years; range 28-71 years) received a total of 128 cycles of therapy (median, 3; range 1-9). Twenty-six patients had recurrent disease and 11 had metastatic tumors. The objective response rate was 32.4% (95% confidence interval = 16.6-48.3%), including 1 complete response and 11 partial responses. Eleven had stable disease, whereas 12 had progressive disease. The median duration of response was 70.5 days (range 30-392 days). Grade 3/4 toxicities included anemia (10.8%), leukopenia (27.0%), neutropenia (51.4%), thrombocytopenia (2.7%), nausea/vomiting (5.4%) and oral mucositis (13.5%). Median time to progression was 136 days and median overall survival was 235 days. The DP combination was well tolerated and effective for patients with metastatic gastric cancer treated previously with 5-fluorouracil/platinum chemotherapy.
    Japanese Journal of Clinical Oncology 01/2006; 35(12):727-32. · 1.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Schwannoma, which arises from the neural sheath of peripheral nerves, is the most common benign tumor in the retroperitoneum in adults. Complete excision is the treatment of choice for retroperitoneal schwannoma. During surgery, it seems to be unnecessary to identify the small peripheral nerve from which it develops. Keeping a dry field, however, through meticulous control of fine vasculature is of primary importance to avoid inadvertent injury to any of the adjacent organs, large vessels or important nerves. There are few vessels, if any, on the anterior and lateral surfaces of the tumor. Numerous small vessels to and from the tumors are located at its posterior and medial (aortic) aspects, without forming large trunks. Harmonic scalpel may be a good armamentarium in this area. In conclusion, considering such multiple small tumor vessels running adjacent to the aorta, the surgeon should pay close attention to the course of central dissection of these tumors in the retroperitoneum.
    Hepato-gastroenterology 01/2005; 52(66):1681-4. · 0.77 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Heptaplatin is a recently developed platinum derivative. This agent has been reported to have a response rate of 17% as a single agent, and tolerable toxicity in the treatment of advanced gastric cancer. The aim of this study was to evaluate the efficacy and toxicity of a combination of 5-fluorouracil (5-FU) and heptaplatin in patients with advanced gastric cancer. Forty-seven chemotherapy-naive patients with advanced or recurred gastric cancer were recruited. 5-FU was administered over 120 hr by continuous intravenous infusion from day 1 to 5, at a daily dose of 1,000 mg/m2 and heptaplatin was administered over 1 hr by intravenous infusion on day 1 at 400 mg/m2, and this cycle was repeated every 4 weeks. The response rate was 21%, median progression-free survival was 1.9 months (95% CI, 1.6 to 2.2 months). Median overall survival was 6.2 months (95% CI, 4 to 8.4 months) and the 1-yr survival rate was 29% for all patients. The most frequent toxicity was proteinuria. Toxicities were generally mild and reversible. This study demonstrates that the combination of 5-FU/heptaplatin combination is less active but tolerated in patients with advance gastric cancer.
    Journal of Korean Medical Science 07/2004; 19(3):369-73. · 1.25 Impact Factor
  • Journal of Korean Medical Science - J KOREAN MED SCI. 01/2004; 19(3).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Not Available
    Science and Technology, 2001. KORUS '01. Proceedings. The Fifth Russian-Korean International Symposium on; 01/2001

Publication Stats

56 Citations
17.70 Total Impact Points


  • 2004–2013
    • Ulsan University Hospital
      Urusan, Ulsan, South Korea
  • 2005
    • University of Ulsan
      • Department of Surgery
      Ulsan, Ulsan, South Korea